Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: Possible transformation of lung adenocarcinoma

Respirology

Volumn 17, Issue 8, 2012, Pages 1275-1277

  Yanagisawa, Satoru ^a   Morikawa, Naoto ^a   Kimura, Yuichiro ^a   Nagano, Yoko ^a   Murakami, Kazuhiro ^b   Tabata, Toshiharu ^c  

^a Departments of Respiratory Medicine   (Japan)

^b Departments of Pathology   (Japan)

^c Tohokukoseinenkin Hospital   (Japan)

Author keywords

epidermal growth factor receptor; epidermal growth factor receptor tyrosine kinase inhibitor; large cell neuroendocrine carcinoma; small cell lung carcinoma; transformation

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE;

ADJUVANT THERAPY; ADULT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; MALE; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VIDEO ASSISTED THORACOSCOPIC SURGERY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; EXONS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; VINBLASTINE;

EID: 84867968006     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02258.x     Document Type: Note

References (5)

1. Lynch TJ, Bell DW, Sordella R, et al,. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-39.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al,. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011; 3: 75ra26.
3. Travis WD, Linnoila RI, Tsokos MG, et al,. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendoc rine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 1991; 15: 529-53.
4. Morinaga R, Okamoto I, Furuta K, et al,. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007; 58: 411-13.
5. De Pas TM, Giovannini M, Manzotti M, et al,. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J. Clin. Oncol. 2011; 29: e819-822.